Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs

Masitinib is an orally acceptable tyrosine kinase inhibitor that is currently investigated under clinical trials against cancer, asthma, Alzheimer’s disease, multiple sclerosis and amyotrophic lateral sclerosis. A recent study confirmed the anti-severe acute respiratory syndrome coronavirus 2 (SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurung, Arun Bahadur, Ali, Mohammad Ajmal, Aljowaie, Reem M., Almutairi, Saeedah M., Sami, Hiba, Lee, Joongku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. on behalf of King Saud University. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651948/
https://www.ncbi.nlm.nih.gov/pubmed/36406239
http://dx.doi.org/10.1016/j.jksus.2022.102397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651948/
https://www.ncbi.nlm.nih.gov/pubmed/36406239
http://dx.doi.org/10.1016/j.jksus.2022.102397

Ejemplares similares